Seizing a Pap smear to catch a criminal? Ethical issues of forensic use of medical biobanks
By Nina de Groot,
Journal of Medical Ethics blog
| 06. 09. 2020
In our paper, we discuss pressing problems with respect to confidentiality, trust, autonomy and justice.
A couple of years ago, during my studies, I assisted with a surgical removal of a benign uterine tumor at a small local hospital. As not much else was happening that day, I decided to follow the tumor out of the operation room all the way down to the pathologist in the basement. After examining the tumor sample, the pathologist opened a couple of doors to the storage rooms. That’s when I found out about the huge archives of tissue material that comprised most of the tiny hospital’s basement. “Oh, but this is not everything”, the pathologist told me, “we keep most of the tissue samples in storage boxes next to the highway”. As the tissue sections were to be stored for 115 years, the archives were bursting at the seams.
Ever since, the vast amount of little human parts scattered across the country has fascinated me. In the years to follow, I would see dusty moving boxes in corridors, high-tech automatically operated storages, and tanks of liquid nitrogen in a hospital’s parking lot. Filled with blood, sperm, tumor samples...
Related Articles
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Ben Fidler and Ned Pagliarulo, Biopharma Dive | 07.21.2025
One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be life-threatening.
The man died...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...